ClinicalTrials.gg
CompletedNCT04318743Updated Jul 14, 2021

A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.

A Phase 1 interventional study of Glepaglutide in Healthy, sponsored by Zealand Pharma. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-14.

Sponsored by Zealand Pharma · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2021, 5 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years to 54 Years
Sex
All
01

Study summary

This is an open-label, randomized, single center, 2-treatment, 3-period, 3-sequence reference-replicated, crossover trial in healthy subjects to compare the PK of glepaglutide (ZP1848) after a single SC administration by vial/syringe and by autoinjector.

Read the detailed description

A total of 72 subjects will be randomized in a 1:1:1 ratio to receive 10 mg glepaglutide SC via vial/syringe (Reference) twice or autoinjector (Test) in one of the 3 treatment sequences.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. obtained before any trial-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject).
  2. Healthy male or female subject aged between 18 years and 54 years, both inclusive, at screening.
  3. (BMI) >20.0 kg/m2 and \<29.9 kg/m2, both inclusive, at screening.
  4. Willing to maintain a stable weight for the duration of the trial.
  5. In overall good health according to age (medical history, physical examination, vital signs, and laboratory assessments), as judged by the Investigator at screening.
  6. Able to comply with all trial procedures.

Exclusion criteria

Exclusion Criteria:

  1. Significant medical history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator.
  2. Subject with a history of colon cancer or a history of other cancers within the last 5 years.
  3. abnormality from physical examination, standard 12-lead , or vital signs measurements as determined by the Investigator.
  4. Clinically significant abnormality in hematology, clinical chemistry, or urinalysis as determined by the Investigator (congenital nonhemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is acceptable).
  5. History of significant , intolerance, suspected hypersensitivity to glepaglutide or related products, or allergy to any drug compound, food, or other substance, unless approved by the Investigator.
  6. Positive results for surface antigens (HbsAg), virus (HCV) antibodies and/or (HIV) 1 antigen or HIV 1/2 antibodies, at screening.
  7. Receipt of blood products within 2 months prior to screening.
  8. Donation of blood or significant blood loss from 8 weeks prior to screening, plasma from 2 weeks prior to screening, or from 6 weeks prior to screening.
  9. Use of any prescription medications/products (other than oral, implantable, transdermal, injectable, or intrauterine hormonal ) within 14 days prior to screening, unless deemed acceptable by the Investigator.
  10. Use of any nonprescription, over-the-counter medication/products, including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations, within 7 days prior to screening unless deemed acceptable by the Investigator. Up to 2 grams per day of acetaminophen is allowed at the discretion of the Investigator.
  11. Use of any medications/products known to be strong inhibitors or strong inducers of cytochrome P450 3A enzyme, including St. John's wort, within 30 days prior to screening, unless deemed acceptable by the Investigator.
  12. Have previously received the product.
  13. Receipt of any investigational product within 60 days prior to screening. Participation in more than 3 other drug studies in the 10 months prior to screening in the current trial.
  14. Previous exposure to glucagon-like peptide-1 (GLP-1), GLP-2, or analogs thereof. Previous exposure to human growth hormone, somatostatin, dipeptidyl peptidase-4 inhibitors, or analogs thereof within 6 months prior to screening.
  15. Have previously completed or withdrawn from this trial or any other trial investigating glepaglutide.
  16. History of alcoholism or drug/chemical abuse within 2 years prior to screening.
  17. Current alcohol consumption of >21 units per week for males and >14 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL wine).
  18. Positive urine drug screen (confirmed by repeat).
  19. Use of tobacco, smoking cessation products, or products containing nicotine (including but not limited to cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine lozenges, or nicotine gum ) within 3 months prior to screening.
  20. Poor peripheral venous access.
  21. Positive qualitative serum pregnancy test (serum human chorionic gonadotropin) (female subjects only).
  22. Female who is pregnant, breastfeeding, intends to become pregnant in the immediate future.
  23. Female subject of who is sexually active without using adequate contraceptive methods (see Section 3.4.8) from 4 weeks prior to first admission to the clinical research center until 3 months after the last dose of trial product.*
  24. Male subject, who is not surgically sterilized and sexually active with a female partner of childbearing potential, and who is not willing to use adequate contraceptive methods (see Section 3.4.8), from the first dosing until 3 months after the last dose of trial product.
  25. Subjects whom, in the opinion of the Investigator, should not participate in this trial.
  26. Employee of PRA or the Sponsor or otherwise dependent. * Participant is of nonchildbearing potential, if she is either surgically sterilized (ie, by tubal ligation or removal of ovaries), has undergone complete hysterectomy, or is in a menopausal state (ie, at least one year without menses and a serum follicle-stimulating hormone [FSH] >40 IU/L at screening).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    autoinjector - vial/syringe - vial/syringe

    Single dose of Glepaglutide 10 mg for each treatment sequence

    Drug: Glepaglutide

  • Experimental
    vial/syringe - autoinjector - vial/syringe

    Single dose of Glepaglutide 10 mg for each treatment sequence

    Drug: Glepaglutide

  • Experimental
    vial/syringe - vial/syringe - autoinjector

    Single dose of Glepaglutide 10 mg for each treatment sequence

    Drug: Glepaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Variables

    Cmax = maximum concentration of ZP1848total in plasma

    Time frame: From time zero to the last time point with a measurable concentration

  2. Pharmacokinetic Variables

    AUC0-t = area under the plasma ZP1848total concentration-time curve (AUC)

    Time frame: from time zero to the last time point with a measurable concentration

Secondary outcomes

  1. Safety Variables

    Number of subject with AE/SAE as a measure of safety and tolerability

    Time frame: 16 weeks

07

Study locations

1 site
  • PRA Health Sciences- Location Martini
    Groningen, NZ 9728, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Jun 2021, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2020
First posted
Mar 24, 2020
StartActual
Mar 4, 2020
Primary completionActual
Jun 10, 2021
CompletionActual
Jun 10, 2021
Last update
Jul 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04318743
Lead sponsor
Zealand Pharma
Responsible party
Sponsor
First posted
Mar 24, 2020
Start date
Mar 4, 2020
Primary completion
Jun 10, 2021
Completion
Jun 10, 2021
Last update
Jul 14, 2021

Study contacts

Stine Just Maarbjerg, PhD
study director · Zealand Pharma A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glepaglutide

Start the discussion